INTERCEPT PHARMACEUTICALS IN - COM (ICPT)

Historical Holders from Q1 2014 to Q4 2023

Symbol: ICPT
Type / Class: Equity / COM
All holders as of 31 Dec 2023: Q4 2023
Total 13F shares, excl. options: 0
Holdings value: $0
Number of holders: 0
Number of sells: -140
Average sells %: -0%

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Institutional Holders of INTERCEPT PHARMACEUTICALS IN - COM (ICPT)

Period	Reported Shares, Excl. Options	Value, Excl. Options	Change	Puts Notional Value	Calls Notional Value	Price	Investors
2023 Q4	0	$0	-$717,520,923	$0	$0		0
2023 Q3	38,829,903	$719,936,195	+$114,245,771	$43,125,794	$15,462,560	$18.54	143
2023 Q2	34,971,157	$386,778,183	+$65,262,601	$14,857,167	$6,944,705	$11.06	123
2023 Q1	28,593,359	$384,023,894	+$1,477,688	$6,555,762	$6,980,645	$13.43	142
2022 Q4	28,549,177	$353,142,578	-$4,999,657	$8,411,600	$8,201,063	$12.37	143
2022 Q3	28,817,205	$401,990,517	+$60,400,362	$16,696,000	$27,477,000	$13.95	148
2022 Q2	24,303,337	$335,549,678	-$206,134	$6,336,884	$20,868,000	$13.81	137
2022 Q1	24,370,010	$396,509,258	-$3,509,843	$9,802,000	$14,570,000	$16.27	142
2021 Q4	24,604,030	$400,575,953	+$35,473,049	$22,832,385	$19,748,000	$16.29	137
2021 Q3	22,273,676	$330,912,225	-$1,999,524	$19,736,025	$10,970,000	$14.85	131
2021 Q2	22,270,837	$444,849,179	-$48,164,534	$18,604,000	$19,591,000	$19.97	126
2021 Q1	24,633,284	$568,533,323	-$49,482,314	$32,800,000	$22,713,000	$23.08	142
2020 Q4	26,718,571	$659,965,411	-$90,243,187	$41,142,100	$29,731,000	$24.7	166
2020 Q3	28,408,511	$1,178,204,417	+$55,478,700	$50,935,000	$45,392,000	$41.46	172
2020 Q2	26,762,333	$1,281,754,949	+$63,166,949	$73,762,000	$64,696,000	$47.91	186
2020 Q1	25,441,646	$1,601,845,507	-$82,212,688	$65,265,000	$70,691,000	$62.96	181
2019 Q4	25,849,561	$3,203,186,181	+$17,921,567	$245,625,000	$232,435,000	$123.92	210
2019 Q3	26,237,550	$1,740,932,311	-$42,337,492	$92,503,000	$94,928,000	$66.36	183
2019 Q2	26,753,528	$2,128,534,998	+$319,846,105	$72,011,000	$91,897,000	$79.57	193
2019 Q1	22,967,654	$2,569,063,573	+$254,710,659	$395,539,000	$213,116,468	$111.86	200
2018 Q4	20,869,742	$2,102,944,344	+$129,805,908	$201,111,000	$147,605,000	$100.79	185
2018 Q3	19,180,997	$2,423,578,574	-$145,246,067	$169,996,000	$179,507,000	$126.36	172
2018 Q2	20,744,536	$1,740,626,547	+$107,286,408	$54,886,000	$89,835,000	$83.91	158
2018 Q1	19,657,035	$1,209,281,804	+$79,552,686	$49,376,000	$59,439,000	$61.52	144
2017 Q4	18,504,038	$1,081,008,395	-$13,098,519	$52,626,000	$74,859,000	$58.42	160
2017 Q3	18,521,451	$1,074,614,778	-$285,250,387	$86,270,000	$104,464,000	$58.04	148
2017 Q2	20,648,023	$2,499,803,066	-$48,280,917	$63,145,000	$111,512,000	$121.07	164
2017 Q1	21,056,541	$2,381,432,291	+$137,674,797	$76,235,000	$104,334,000	$113.1	149
2016 Q4	20,807,747	$2,260,740,338	-$18,776,198	$140,540,000	$143,520,000	$108.65	157
2016 Q3	20,523,914	$3,376,925,666	+$44,308,851	$152,801,000	$208,251,000	$164.59	167
2016 Q2	20,353,887	$2,906,331,474	+$221,979,092	$132,774,000	$196,105,000	$142.68	163
2016 Q1	18,835,025	$2,419,329,232	+$23,602,056	$137,260,000	$65,893,000	$128.47	156
2015 Q4	18,559,218	$2,771,842,810	-$15,430,911	$97,798,000	$70,059,438	$149.35	163
2015 Q3	18,601,899	$3,085,693,628	+$69,994,780	$82,997,000	$71,685,000	$165.86	169
2015 Q2	18,056,758	$4,359,366,474	+$41,949,643	$128,053,000	$108,934,000	$241.38	189
2015 Q1	17,750,268	$5,002,997,878	+$659,415,345	$203,196,000	$200,262,000	$282.02	199
2014 Q4	15,524,823	$2,422,618,787	+$357,006,384	$92,570,000	$50,560,000	$156	168
2014 Q3	12,919,477	$3,057,974,702	-$38,046,344	$170,136,000	$101,422,000	$236.69	178
2014 Q2	13,082,269	$3,095,022,572	+$44,360,145	$224,676,000	$91,030,000	$236.63	164
2014 Q1	12,472,096	$4,111,281,844	+$498,327,735	$40,131,000	$87,126,000	$329.79	169